Pharmacosmos investigates anemia treatment in new patient group
A new phase III study will shed light on the efficacy of Pharmacosmos's Monoferric/Monofer in children and adolescents. This patient segment has not been eligible for the iron deficiency anemia treatment before.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Danish Pharmacosmos is on the hunt for 200 patients between the ages 0 and 18 for a clinical phase III trial involving intravenous injection treatment Monoferric, also known as Monofer, for iron deficiency anemia (IDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
